Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2024-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
大信会计师事务所（特殊普通合伙）关于辰欣药业股份有限公司2023年度审计报告
Regulatory Filings
2024-04-22 Chinese
辰欣药业股份有限公司关于2023年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of the company, including details on cash dividends per share, the total amount of dividends, and the approval process by the board and supervisory committee. It explicitly states that the profit distribution plan still needs to be submitted to the shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on dividend distribution details and procedural approvals. The length is short (1795 characters), and the content is typical of a Notice of Dividend Amount announcement rather than a full Annual Report or Earnings Release. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2024-04-22 Chinese
辰欣药业股份有限公司关于使用部分闲置的自有资金进行委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the progress of using part of its idle funds for entrusted financial management products. It includes specifics about the financial products purchased, amounts, expected returns, overdue payments, legal actions taken, and repayment plans. The document is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a regulatory announcement about financing activities related to entrusted financial products and their status, including risk disclosures and legal proceedings related to these financial products. This fits best under the category of Capital/Financing Update (CAP), as it provides updates on the company's financing activities and capital usage related to entrusted financial products.
2024-04-22 Chinese
辰欣药业股份有限公司第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's fifth board meeting, including approval of the 2023 annual report, board work report, independent directors' reports, audit committee reports, financial statements, profit distribution plan, internal control evaluation, fundraising usage report, related party transactions, remuneration plans, auditor appointment, and appointment of senior management. It also includes approval of the 2024 Q1 report and the proposal to convene the 2023 annual shareholders meeting. The document references multiple reports and states that the full reports are disclosed on the Shanghai Stock Exchange website, indicating this document itself is a board meeting resolution announcement rather than the reports themselves. The content focuses on board decisions and management appointments, including the appointment of a new CFO and deputy general manager. Therefore, the document is best classified as Board/Management Information (MANG). The document length (8147 characters) and detailed content support this classification rather than a brief announcement or a full annual report.
2024-04-22 Chinese
辰欣药业股份有限公司第五届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of a company regarding the approval of various reports and proposals including the 2023 Annual Report, Supervisory Board Work Report, financial statements, profit distribution plan, internal control evaluation, fundraising usage report, related party transactions, remuneration for supervisors, auditor reappointment, and the 2024 Q1 report. The document states that the actual reports are disclosed separately on the Shanghai Stock Exchange website and that these resolutions will be submitted to the shareholders' meeting for approval. The document length is under 5,000 characters and primarily serves as an announcement of the Supervisory Board's meeting decisions rather than the reports themselves. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal regulatory announcement of meeting resolutions and approvals, not the full reports or financial statements themselves.
2024-04-22 Chinese
辰欣药业股份有限公司关于2023年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Annual Special Report on the Deposit and Use of Raised Funds" by a listed company. It details the management, usage, and balance of funds raised through a public offering, including specific investment projects, changes in project allocations, cash management of idle funds, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document includes detailed financial figures related to fundraising and usage, project progress, and regulatory compliance. It is a specialized report focused on the use of raised capital rather than a full annual report or earnings release. This type of document aligns with a Capital/Financing Update (CAP) as it provides updates on fundraising and capital usage activities. The document length is substantial and contains detailed financial data, confirming it is a report rather than a brief announcement or certification. Therefore, the appropriate classification is CAP.
2024-04-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.